Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.

about

Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.

Item

http://www.wikidata.org/entity/Q35914818

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Efficacy and Safety of an Acli ...... -Severe COPD: A Meta-Analysis.

@ast

Efficacy and Safety of an Acli ...... -Severe COPD: A Meta-Analysis.

@en

type

Item

label

Efficacy and Safety of an Acli ...... -Severe COPD: A Meta-Analysis.

@ast

Efficacy and Safety of an Acli ...... -Severe COPD: A Meta-Analysis.

@en

prefLabel

Efficacy and Safety of an Acli ...... -Severe COPD: A Meta-Analysis.

@ast

Efficacy and Safety of an Acli ...... -Severe COPD: A Meta-Analysis.

@en

P1476

Efficacy and Safety of an Acli ...... -Severe COPD: A Meta-Analysis.

@en

P2093

Dan Hui Yang

http://www.w3.org/2001/XMLSchema#string

Jian Xiao

http://www.w3.org/2001/XMLSchema#string

Jun Li

http://www.w3.org/2001/XMLSchema#string

Qiong Chen

http://www.w3.org/2001/XMLSchema#string

Yong Zou

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

Anticholinergic therapy for airway diseases.

Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.

Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

Safety and tolerability of inhalational anticholinergics in COPD

Global burden of COPD: risk factors, prevalence, and future trends.

P304

499-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.3109/15412555.2015.1074172

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26846588

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease